The Palvella Therapeutics, Inc. (Nasdaq: PVLA) SEC filings page on Stock Titan provides access to the company’s official disclosures as a clinical-stage biopharmaceutical issuer. Palvella’s filings describe a business focused on developing investigational topical therapies for serious, rare skin diseases and vascular malformations with no FDA-approved therapies, built around its patented QTORIN™ platform.
Through documents such as Form 8-K current reports, investors can review how Palvella communicates material events, including topline results from the Phase 2 TOIVA trial of QTORIN™ rapamycin for cutaneous venous malformations, updates on the Phase 3 SELVA trial in microcystic lymphatic malformations, and announcements of new product candidates like QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis. Other 8-K filings furnish earnings press releases, corporate presentations, and information about conference calls related to quarterly financial results and corporate updates.
These filings also confirm key structural details, such as Palvella’s incorporation in Nevada, its listing of common stock on The Nasdaq Capital Market under the symbol PVLA, and its description as a clinical-stage company. Regulation FD disclosures provide slide decks and presentations that elaborate on the company’s pipeline, regulatory designations, and development plans, while results-of-operations filings supply context on research and development spending and general and administrative costs associated with advancing QTORIN™ programs.
On Stock Titan, users can combine real-time updates from EDGAR with AI-assisted views of Palvella’s filings to more quickly understand the significance of new 8-Ks and related exhibits. This includes identifying which filings discuss clinical data, regulatory interactions, or financial performance, and how those disclosures relate to the company’s investigational product candidates, all while recognizing that QTORIN™ rapamycin and QTORIN™ pitavastatin remain unapproved therapies.
PALVELLA THERAPEUTICS, INC. (PVLA) officer Kathleen Goin reported a proposed sale of 4,313 common shares, with an aggregate market value of $534,466.96 and an approximate sale date of October 21, 2026. Piper Sandler & Co. Inc. is listed as broker, and Nasdaq as the exchange. The 4,313 shares are listed as acquired from the issuer through a stock option exercise for cash on October 21, 2026. The notice also lists three prior sales of 4,302 shares each: July 15 for $642,191.37, August 19 for $654,791.07, and September 16, 2026 for $654,922.71.
Palvella Therapeutics, Inc. director George M. Jenkins directly sold 27,500 shares of common stock in transactions on October 12, 2026, October 13, 2026, and October 14, 2026, under a Rule 10b5-1 trading plan adopted on June 12, 2026. Reported weighted-average prices included $132.6165 per share for 5,095 shares sold October 12, 2026, $128.5206 per share for 2,004 shares sold October 13, 2026, and $121.1403 per share for 476 shares sold October 14, 2026.
Palvella Therapeutics, Inc. (PVLA) is the issuer for director George Jenkins’s proposed sale of 27,500 common shares through Piper Sandler & Co., with an approximate sale date of October 13, 2026. The reported aggregate market value is $3,695,450.00; 14,408,407 shares are listed as outstanding. Earlier sales listed for Jenkins were 12,371 shares on September 11, 13,352 on September 14, and 1,777 on September 15, 2026.
PALVELLA THERAPEUTICS, INC. (PVLA) reported that Chief Operating Officer Kathleen Goin exercised stock options for a total of 4,302 shares of common stock on September 16, 2026, at exercise prices of $7.14 and $9.08 per share and then sold 4,302 shares in multiple transactions. These trades were made pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025, as disclosed in the filing.
PALVELLA THERAPEUTICS, INC. (PVLA) is the issuer of common stock that officer Kathleen Goin plans to sell under Rule 144. The notice covers a proposed sale of 4,302 shares of common stock through Piper Sandler & Co on Nasdaq on September 16, 2026, following a cash stock option exercise with Palvella as issuer.
Goin also reported prior Rule 144 sales of 4,302 shares of Palvella common stock on each of June 17, 2026, July 15, 2026, and August 19, 2026, with reported aggregate values in the hundreds of thousands of dollars for each transaction. Piper Sandler signed the notice as attorney-in-fact for Goin.
Palvella Therapeutics, Inc. (PVLA) director George M. Jenkins reported open-market sales of 27,500 shares of common stock over September 11–15, 2026, at weighted-average prices generally between about $149 and $153 per share. The transactions were effected under a Rule 10b5-1 trading plan adopted on June 12, 2026. Following these transactions, an entity described as Eagles Mere Air Museum Foundation holds 13,516 shares indirectly.
Palvella Therapeutics, Inc. (PVLA) director George M. Jenkins filed a notice of proposed sale of 27,500 shares of common stock under Rule 144. The shares were originally acquired on March 6, 2017 through a private investment for cash and are expected to be sold through Piper Sandler on NASDAQ.
PALVELLA THERAPEUTICS, INC. (PVLA) director Christopher P. Kiritsy reported an option exercise and related share sale. On September 2, 2026, he exercised a fully vested stock option for 313 shares of common stock at an exercise price of $127.20 per share, a figure adjusted for the company’s 1-for-80 reverse stock split that became effective on April 23, 2024. He then sold 313 shares of common stock at $157.00 per share on the same date, and the exercised option position is reported as fully exhausted in this filing.
PALVELLA THERAPEUTICS, INC. (PVLA) is the issuer for a proposed sale of common stock reported under Rule 144 by stockholder Christopher Kiritsy. The notice covers 375 shares of common stock, with an indicated value of $58,875.00, to be sold through Morgan Stanley Smith Barney LLC on or after September 2, 2026.
The shares are to be issued in connection with a stock option exercise, with the issuer listed as the party for the option exercise and cash as the form of payment. The securities are listed as trading on NASDAQ.
PALVELLA THERAPEUTICS, INC. (PVLA) reported that Chief Operating Officer Kathleen Goin exercised stock options covering 4,302 shares of common stock on August 19, 2026, at exercise prices of $7.14 and $9.08 per share, and sold 4,302 shares in multiple open-market transactions at prices between $150.62 and $156.77 per share. These trades were executed under a Rule 10b5-1 trading plan adopted on August 19, 2025, and the exercised options were fully vested.